Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Cash: 2019-2025

Historic Change in Cash for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$19.3 million.

  • C4 Therapeutics' Change in Cash fell 43.69% to -$19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$840,000, marking a year-over-year increase of 36.98%. This contributed to the annual value of -$71.1 million for FY2024, which is 173.29% down from last year.
  • Per C4 Therapeutics' latest filing, its Change in Cash stood at -$19.3 million for Q3 2025, which was down 172.02% from $26.9 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Change in Cash peaked at $184.9 million during Q2 2021, and registered a low of -$118.4 million during Q3 2021.
  • In the last 3 years, C4 Therapeutics' Change in Cash had a median value of -$4.2 million in 2025 and averaged $2.7 million.
  • The largest annual percentage gain for C4 Therapeutics' Change in Cash in the last 5 years was 447.19% (2021), contrasted with its biggest fall of 420.04% (2021).
  • Over the past 5 years, C4 Therapeutics' Change in Cash (Quarterly) stood at -$84.6 million in 2021, then skyrocketed by 76.60% to -$19.8 million in 2022, then surged by 431.40% to $65.6 million in 2023, then plummeted by 106.33% to -$4.2 million in 2024, then tumbled by 43.69% to -$19.3 million in 2025.
  • Its last three reported values are -$19.3 million in Q3 2025, $26.9 million for Q2 2025, and -$4.2 million during Q1 2025.